Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

NCT06739395 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumor
Precision Medicine

Interventions

DRUG: Olaparib tablet
DRUG: Temozolomide capsule
DRUG: Anlotinib
DRUG: Trametinib tablet
DRUG: Dabrafenib
DRUG: Vebreltinib Enteric Capsules
DRUG: Alpelisib Pill
DRUG: Sacituzumab Govitecan-Hziy 180 MG
DRUG: Lenvatinib Capsules
DRUG: Pazopanib Pill
DRUG: Palbociclib Pill
DRUG: Chidamide
DRUG: PD-1/PD-L1/PD-1&CTLA4 inhibitor
DRUG: Target Gene

Sponsor

Tianjin Medical University Second Hospital